Flow Cytometry Improved Updated Spectral Analyzer
|
By LabMedica International staff writers Posted on 31 Oct 2019 |

Image: The Aurora advanced flow cytometry system is now available with five lasers to enable seeing more than 30 colors from a single sample (Photo courtesy of Cytek Biosciences).
Flow cytometry aims to count the number, size, granularity, and other properties of cells in a heterogeneous population. Standard flow cytometry lasers excite certain fluorescent markers (fluorochromes, antibodies, or stains) on a cell as it passes through the beam.
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Detectors in the instrument record and quantify the relative amount of light emitted by fluorescent markers in the cell, which the tool presents to scientists through a histogram. However, flow cytometer users can run into a myriad of technical issues, such as dealing with limited sample volumes and lacking enough lasers to excite a target amount of fluorochromes. Each laser also can only excite a certain number of fluorochromes on a cell before inducing spectral overlap.
An updated model of its Aurora flow cytometry system has been released by Cytek Biosciences (Fremont, CA, USA), which offers scientists the ability to multiplex 40 fluorescent biomarkers on a cell in a blood sample for scientific and clinical purposes. The updated Aurora platform uses five optical lasers (ultraviolet, violet, blue, yellow-green, and red) to excite 40 fluorochromes on cellular antibodies, which are then recorded by 64 detectors.
With standard flow cytometry panels, a patient's blood sample must be separated into multiple tubes to identify biomarkers linked to different types of leukemia; however the Aurora platform only needs a single tube of blood to identify the fluorescent antibodies. While scientists still need to run controls prior to running a multicolor tube to measure the different emission spectra recorded by Aurora, they can save the controls in the software and reuse them with the same panel in future tests.
Wenbin Jiang, PhD, CEO of Cytek Biosciences, said, “After chemotherapy, no one really has that many bone marrow samples available for testing and splitting into several different tubes. But because you don't need to split blood samples into several tubes with Aurora, you can have more cells per tube, which leads to more specific results." Dr. Jiang also argued that the updated Aurora system can analyze up to 30,000 to 40,000 cells per second while maintaining a "competitive sensitivity." Flow cytometry platforms on the market currently offer anywhere from 20,000 to 100,000 cells per second, but not always at the sample level of multiplexing.
Steven A. Porcelli, MD, scientific director at the Albert Einstein College of Medicine Flow Cytometry Core (Bronx, NY, USA), said, “Cytek's tool collected light coming out over a wide range of wavelengths for each cell and for each laser that we've used to excite the cell. Instead of giving you a high or low value for a tracer, it allows you to distinguish many different tracers from each other because you create a kind of fingerprint of the wavelengths being emitted.”
Related Links:
Cytek Biosciences
Albert Einstein College of Medicine Flow Cytometry Core
Latest Technology News
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
- Training Device Improves Accuracy of Pooled Molecular Diagnostics
- New CE-Certified Software Advances Whole-Genome Cancer Testing
- National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
- AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
- Agentic AI Platform Supports Genomic Decision-Making in Oncology
- Algorithm Panel Aids Liver Fibrosis Assessment and Liver Cancer Surveillance
- Mailed Screening Kits Help Reduce Colorectal Cancer Screening Gaps
- AI-Enabled Assistant Unifies Molecular Workflow Planning and Support
- AI Tool Automates Validation of Laboratory Software Configuration Changes
- Point-of-Care Testing Enhances Health Literacy and Self-Management in Chronic Disease
- Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
- Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
- New Platform Captures Extracellular Vesicles for Early Cancer Detection
- Microfluidic Single-Cell Assay Predicts Breast Cancer Risk
- AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Channels
Clinical Chemistry
view channel
Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more
Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read moreMolecular Diagnostics
view channel
Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy
Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more
Blood Test Could Help Fast-Track Lymphoma Diagnosis in Resource-Limited Settings
Lymphoma can be difficult to distinguish from infections and benign conditions, while definitive diagnosis often depends on surgical tissue sampling and specialized pathology that may not be readily available.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Study Reveals Viral Protein Driving COVID-19-Related Vascular Injury
Lingering symptoms after acute COVID-19 infection remain a clinical challenge, with many patients experiencing fatigue, cognitive problems, and cardiovascular complications months later.... Read more
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read moreMicrobiology
view channel
Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read moreProteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
The intestinal microbiome influences digestion, metabolism, and immunity, yet its complexity makes functional measurements difficult to obtain. DNA surveys can indicate which organisms and potential pathways... Read more
Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
Serious lung infections remain a major cause of morbidity among people with cystic fibrosis, a life-threatening genetic disorder characterized by persistent airway colonization and frequent antimicrobial exposure.... Read morePathology
view channel
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreIndustry
view channel
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







